{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:15:43Z","timestamp":1789604143445,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","issue":"39","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.vaccine.2013.03.020","type":"journal-article","created":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T09:38:33Z","timestamp":1363858713000},"page":"4241-4246","source":"Crossref","is-referenced-by-count":145,"title":["Clinical development of Modified Vaccinia virus Ankara vaccines"],"prefix":"10.1016","volume":"31","author":[{"given":"Sarah C.","family":"Gilbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.vaccine.2013.03.020_bib0005","doi-asserted-by":"crossref","first-page":"455","DOI":"10.5694\/j.1326-5377.1980.tb135034.x","article-title":"The global eradication of smallpox","volume":"1","author":"Fenner","year":"1980","journal-title":"Med J Aust"},{"issue":"Pt 1","key":"10.1016\/j.vaccine.2013.03.020_bib0010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1099\/vir.0.19565-0","article-title":"Poxvirus genomes: a phylogenetic analysis","volume":"85","author":"Gubser","year":"2004","journal-title":"J Gen Virol"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2013.03.020_bib0015","doi-asserted-by":"crossref","first-page":"D73","DOI":"10.1016\/j.vaccine.2009.07.103","article-title":"Smallpox vaccines for biodefense","volume":"27","author":"Kennedy","year":"2009","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2013.03.020_bib0020","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/infdis\/jiq162","article-title":"Smallpox vaccine safety is dependent on T cells and not B cells","volume":"203","author":"Gordon","year":"2011","journal-title":"J Infect Dis"},{"issue":"5,6","key":"10.1016\/j.vaccine.2013.03.020_bib0025","first-page":"375","article-title":"The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)","volume":"167","author":"Mayr","year":"1978","journal-title":"Zentralbl Bakteriol B"},{"issue":"Pt 12","key":"10.1016\/j.vaccine.2013.03.020_bib0030","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1099\/vir.0.83156-0","article-title":"Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara","volume":"88","author":"Meisinger-Henschel","year":"2007","journal-title":"J Gen Virol"},{"issue":"Pt 5","key":"10.1016\/j.vaccine.2013.03.020_bib0035","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1099\/0022-1317-72-5-1031","article-title":"Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence","volume":"72","author":"Meyer","year":"1991","journal-title":"J Gen Virol"},{"issue":"Pt 5","key":"10.1016\/j.vaccine.2013.03.020_bib0040","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine","volume":"79","author":"Blanchard","year":"1998","journal-title":"J Gen Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2013.03.020_bib0045","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/viro.1997.8845","article-title":"Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line","volume":"238","author":"Carroll","year":"1997","journal-title":"Virology"},{"issue":"19","key":"10.1016\/j.vaccine.2013.03.020_bib0050","doi-asserted-by":"crossref","first-page":"9907","DOI":"10.1128\/JVI.00756-10","article-title":"Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice","volume":"84","author":"Meisinger-Henschel","year":"2010","journal-title":"J Virol"},{"issue":"27","key":"10.1016\/j.vaccine.2013.03.020_bib0055","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1016\/S0264-410X(01)00075-5","article-title":"Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques","volume":"19","author":"Stittelaar","year":"2001","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.vaccine.2013.03.020_bib0060","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1073\/pnas.89.22.10847","article-title":"Nonreplicating vaccinia vector efficiently expresses recombinant genes","volume":"89","author":"Sutter","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2013.03.020_bib0065","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/978-1-4899-1382-1_2","article-title":"Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates","volume":"397","author":"Moss","year":"1996","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"10.1016\/j.vaccine.2013.03.020_bib0070","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1002\/eji.1830260841","article-title":"Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization","volume":"26","author":"Allsopp","year":"1996","journal-title":"Eur J Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2013.03.020_bib0075","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/nbt1197-1280","article-title":"A protein particle vaccine containing multiple malaria epitopes","volume":"15","author":"Gilbert","year":"1997","journal-title":"Nat Biotechnol"},{"issue":"12","key":"10.1016\/j.vaccine.2013.03.020_bib0080","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1002\/(SICI)1521-4141(199812)28:12<4345::AID-IMMU4345>3.0.CO;2-P","article-title":"Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use","volume":"28","author":"Plebanski","year":"1998","journal-title":"Eur J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2013.03.020_bib0085","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nm0498-397","article-title":"Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara","volume":"4","author":"Schneider","year":"1998","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.vaccine.2013.03.020_bib0090","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1515\/BC.1999.041","article-title":"Ty virus-like particles: DNA vaccines and modified vaccinia virus Ankara; comparisons and combinations","volume":"380","author":"Gilbert","year":"1999","journal-title":"Biol Chem"},{"issue":"7,8","key":"10.1016\/j.vaccine.2013.03.020_bib0095","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0264-410X(99)00278-9","article-title":"Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models","volume":"18","author":"Degano","year":"1999","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2013.03.020_bib0100","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1016\/S0264-410X(01)00260-2","article-title":"A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees","volume":"19","author":"Schneider","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.020_bib0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-065X.1999.tb01326.x","article-title":"Induction of CD8+ T cells using heterologous prime-boost immunisation strategies","volume":"170","author":"Schneider","year":"1999","journal-title":"Immunol Rev"},{"issue":"17,18","key":"10.1016\/j.vaccine.2013.03.020_bib0110","first-page":"2004","article-title":"Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers","volume":"21","author":"Moorthy","year":"2003","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2013.03.020_bib0115","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nm881","article-title":"Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans","volume":"9","author":"McConkey","year":"2003","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.vaccine.2013.03.020_bib0120","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1086\/378515","article-title":"Safety and immunogenicity of DNA\/modified vaccinia virus Ankara malaria vaccination in African adults","volume":"188","author":"Moorthy","year":"2003","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2013.03.020_bib0125","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1371\/journal.pmed.0010033","article-title":"A randomised, double-blind, controlled vaccine efficacy trial of DNA\/MVA ME-TRAP against malaria infection in Gambian adults","volume":"1","author":"Moorthy","year":"2004","journal-title":"PLoS Med"},{"issue":"5","key":"10.1016\/j.vaccine.2013.03.020_bib0130","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.4049\/jimmunol.172.5.3094","article-title":"Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus","volume":"172","author":"Anderson","year":"2004","journal-title":"J Immunol"},{"issue":"13","key":"10.1016\/j.vaccine.2013.03.020_bib0135","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1073\/pnas.0406381102","article-title":"Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara","volume":"102","author":"Webster","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.vaccine.2013.03.020_bib0140","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.4049\/jimmunol.175.9.5675","article-title":"Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria","volume":"175","author":"Keating","year":"2005","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2013.03.020_bib0145","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1086\/501459","article-title":"Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens: ME-TRAP or the circumsporozoite protein, in children and adults in Kenya","volume":"42","author":"Bejon","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"22","key":"10.1016\/j.vaccine.2013.03.020_bib0150","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1016\/j.vaccine.2006.03.029","article-title":"Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1\u20136 year old children in a malaria endemic area","volume":"24","author":"Bejon","year":"2006","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2013.03.020_bib0155","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1371\/journal.pctr.0010029","article-title":"A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya","volume":"1","author":"Bejon","year":"2006","journal-title":"PLoS Clin Trials"},{"issue":"6","key":"10.1016\/j.vaccine.2013.03.020_bib0160","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.4049\/jimmunol.179.6.4193","article-title":"The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum","volume":"179","author":"Bejon","year":"2007","journal-title":"J Immunol"},{"issue":"7,8","key":"10.1016\/j.vaccine.2013.03.020_bib0165","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0264-410X(01)00450-9","article-title":"Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes","volume":"20","author":"Gilbert","year":"2002","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2013.03.020_bib0170","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"issue":"115","key":"10.1016\/j.vaccine.2013.03.020_bib0175","doi-asserted-by":"crossref","first-page":"115ra2","DOI":"10.1126\/scitranslmed.3002925","article-title":"Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species","volume":"4","author":"Colloca","year":"2012","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.vaccine.2013.03.020_bib0180","doi-asserted-by":"crossref","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.vaccine.2013.03.020_bib0185","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jir850","article-title":"Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector","volume":"205","author":"O\u2018Hara","year":"2012","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2013.03.020_bib0190","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/mt.2011.176","article-title":"Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors","volume":"19","author":"Sheehy","year":"2011","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2013.03.020_bib0195","doi-asserted-by":"crossref","first-page":"e31208","DOI":"10.1371\/journal.pone.0031208","article-title":"Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors","volume":"7","author":"Sheehy","year":"2012","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.vaccine.2013.03.020_bib0200","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2567.2011.03517.x","article-title":"T-cell-inducing vaccines \u2013 what's the future","volume":"135","author":"Gilbert","year":"2012","journal-title":"Immunology"},{"issue":"11","key":"10.1016\/j.vaccine.2013.03.020_bib0205","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1128","article-title":"Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans","volume":"10","author":"McShane","year":"2004","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.vaccine.2013.03.020_bib0210","doi-asserted-by":"crossref","first-page":"e5264","DOI":"10.1371\/journal.pone.0005264","article-title":"MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques","volume":"4","author":"Verreck","year":"2009","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.vaccine.2013.03.020_bib0215","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1128\/IAI.00287-09","article-title":"Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis","volume":"77","author":"Vordermeier","year":"2009","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2013.03.020_bib0220","first-page":"124","article-title":"MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults","volume":"12","author":"Nicol","year":"2010","journal-title":"Curr Opin Mol Ther"},{"issue":"1","key":"10.1016\/j.vaccine.2013.03.020_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciq015","article-title":"Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine: MVA-NP+ M1","volume":"52","author":"Berthoud","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2013.03.020_bib0230","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cis327","article-title":"A preliminary assessment of the efficacy of a T cell-based influenza vaccine, MVA-NP+ M1, in humans","author":"Lillie","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"51","key":"10.1016\/j.vaccine.2013.03.020_bib0235","doi-asserted-by":"crossref","first-page":"6671","DOI":"10.1016\/j.vaccine.2008.09.016","article-title":"Lessons from IAVI-006 a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers","volume":"26","author":"Guimaraes-Walker","year":"2008","journal-title":"Vaccine"},{"issue":"46","key":"10.1016\/j.vaccine.2013.03.020_bib0240","doi-asserted-by":"crossref","first-page":"8309","DOI":"10.1016\/j.vaccine.2011.08.098","article-title":"Safety and immunogenicity of a modified pox vector-based HIV\/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: a phase I clinical trial (RISVAC02)","volume":"29","author":"Garcia","year":"2011","journal-title":"Vaccine"},{"issue":"45","key":"10.1016\/j.vaccine.2013.03.020_bib0245","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1016\/j.vaccine.2010.08.077","article-title":"Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects","volume":"28","author":"Howles","year":"2010","journal-title":"Vaccine"},{"issue":"46","key":"10.1016\/j.vaccine.2013.03.020_bib0250","doi-asserted-by":"crossref","first-page":"8417","DOI":"10.1016\/j.vaccine.2011.08.001","article-title":"Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania","volume":"29","author":"Bakari","year":"2011","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2013.03.020_bib0255","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1086\/592507","article-title":"Broad immunogenicity of a multigene: multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara","volume":"198","author":"Sandstrom","year":"2008","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2013.03.020_bib0260","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/10430340460745757","article-title":"Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1: CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus","volume":"15","author":"Corona Gutierrez","year":"2004","journal-title":"Hum Gene Ther"},{"issue":"6","key":"10.1016\/j.vaccine.2013.03.020_bib0265","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.cgt.7700937","article-title":"Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine","volume":"13","author":"Garcia-Hernandez","year":"2006","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"10.1016\/j.vaccine.2013.03.020_bib0270","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00063030-200721010-00006","article-title":"MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I\/II study","volume":"21","author":"Albarran","year":"2007","journal-title":"BioDrugs"},{"key":"10.1016\/j.vaccine.2013.03.020_bib0275","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/157339410791202583","article-title":"HPV and therapeutic vaccines where are we in 2010?","volume":"6","author":"Ma","year":"2010","journal-title":"Curr Cancer Ther Rev"},{"issue":"12","key":"10.1016\/j.vaccine.2013.03.020_bib0280","doi-asserted-by":"crossref","first-page":"8431","DOI":"10.4049\/jimmunol.175.12.8431","article-title":"Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara","volume":"175","author":"Smith","year":"2005","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2013.03.020_bib0285","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/infdis\/jiq105","article-title":"Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles","volume":"203","author":"Goepfert","year":"2011","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2013.03.020_bib0290","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00262-005-0096-4","article-title":"Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated","volume":"55","author":"Harrop","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2013.03.020_bib0295","first-page":"67","article-title":"Clinical efficacy of TroVax in the treatment of progressive castration-resistant prostate cancer. Clinical medicine insights","volume":"6","author":"Amato","year":"2012","journal-title":"Oncology"},{"issue":"22","key":"10.1016\/j.vaccine.2013.03.020_bib0300","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-10-2082","article-title":"Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study","volume":"16","author":"Amato","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2013.03.020_bib0305","article-title":"Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax)","volume":"CII","author":"Harrop","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2013.03.020_bib0310","doi-asserted-by":"crossref","first-page":"e40167","DOI":"10.1371\/journal.pone.0040167","article-title":"Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA","volume":"7","author":"Orubu","year":"2012","journal-title":"PLoS ONE"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13003046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13003046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T04:43:55Z","timestamp":1595565835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13003046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":62,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0264410X13003046"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.03.020","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}